Suppr超能文献

60例上颌鳞状细胞癌的临床分析

[Clinical analysis of 60 cases with maxillary squamous cell carcinoma].

作者信息

Zhang Zai-xing, Li Zheng-jiang, Xu Zhen-gang, Tang Ping-zhang, Zhang Zong-min, An Chang-ming

机构信息

Department of Head and Neck Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.

出版信息

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Jul;45(7):560-4.

Abstract

OBJECTIVE

To study the clinical characters, treatment modalities and prognosis of patients with maxillary squamous cell carcinoma.

METHODS

The clinical data of 60 patients with maxillary squamous cell carcinoma treatment between January 1994 and December 2004 were analyzed retrospectively. The patients were treated with three therapy modalities including radiotherapy alone (22 cases), radiotherapy and surgery (R + S, 29 cases) and concurrent chemo-radio-therapy adjuvant surgery (CCR + S, 9 cases).

RESULTS

The five year survival rate were 18.2%, 51.7% and 33.3% for patients in the radiotherapy alone group, the R + S group and the CCR + S group, respectively. Patients receiving R + S combined modality therapy had a significantly higher five year survival rate than the patients who were treated radiotherapy alone (χ(2) = 15.62, P < 0.01). The five year survival rate (51.7%) of patients in R + S group was significantly higher than that (33.3%) of patients in CCR + S group (χ(2) = 4.28, P < 0.05), and also higher than that (18.2%) of patients in radiotherapy group (χ(2) = 9.49, P < 0.01).

CONCLUSIONS

The combined therapy of radiation and surgery was a good choice of treatment for the patients with maxillary sinus squamous cell carcinoma. The role of concurrent chemo-radiotherapy adjuvant surgery in the treatment of maxillary sinus squamous cell carcinoma needs further to research.

摘要

目的

研究上颌鳞状细胞癌患者的临床特征、治疗方式及预后。

方法

回顾性分析1994年1月至2004年12月期间接受治疗的60例上颌鳞状细胞癌患者的临床资料。患者接受了三种治疗方式,包括单纯放疗(22例)、放疗联合手术(R + S,29例)以及同步放化疗辅助手术(CCR + S,9例)。

结果

单纯放疗组、R + S组和CCR + S组患者的五年生存率分别为18.2%、51.7%和33.3%。接受R + S联合治疗方式的患者五年生存率显著高于单纯接受放疗的患者(χ(2)=15.62,P < 0.01)。R + S组患者的五年生存率(51.7%)显著高于CCR + S组患者的五年生存率(33.3%)(χ(2)=4.28,P < 0.05),也高于放疗组患者的五年生存率(18.2%)(χ(2)=9.49,P < 0.01)。

结论

放疗与手术联合治疗是上颌窦鳞状细胞癌患者的良好治疗选择。同步放化疗辅助手术在上颌窦鳞状细胞癌治疗中的作用有待进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验